KeyBanc Capital Markets initiated coverage on Simulations Plus with a new price target
$SLP
EDP Services
Technology
KeyBanc Capital Markets initiated coverage of Simulations Plus with a rating of Overweight and set a new price target of $47.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/15/2024 | $39.00 | Overweight | Stephens |
| 7/29/2024 | $47.00 | Overweight | KeyBanc Capital Markets |
| 7/16/2024 | Mkt Perform | JMP Securities | |
| 6/28/2024 | Outperform | William Blair | |
| 5/9/2023 | $55.00 | Buy | BTIG Research |
| 10/26/2021 | $65.00 → $53.00 | Hold → Buy | Craig Hallum |
| 7/13/2021 | $95.00 → $54.00 | Outperform | Raymond James |
JMP Securities analyst Constantine Davides initiates coverage on Simulations Plus (NASDAQ:SLP) with a Market Perform rating.
Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicalsSimulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced a newly funded research project with the International Collaboration on Cosmetics Safety (ICCS) to evaluate the use of physiologically-based kinetic (PBK) modeling approaches to advance animal-free science for cosmetics and other non-pharmaceutical ingredients.In a competitive bidding process, Simulations Plus was selected for its propos
Craig-Hallum analyst Matt Hewitt reiterates Simulations Plus (NASDAQ:SLP) with a Buy and maintains $56 price target.
Stephens initiated coverage of Simulations Plus with a rating of Overweight and set a new price target of $39.00
KeyBanc Capital Markets initiated coverage of Simulations Plus with a rating of Overweight and set a new price target of $47.00
JMP Securities initiated coverage of Simulations Plus with a rating of Mkt Perform
4 - Simulations Plus, Inc. (0001023459) (Issuer)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that Shawn O'Connor, chief executive officer, will participate in the virtual BTIG Digital Health Forum on Monday, November 25, 2024. Mr. O'Connor will join a panel discussion entitled "Supporting Drug Development, Clinical Trials, and Biopharma" at 2:00 p.m. Eastern Time. In addition, Mr. O'Connor will host one-on-one meetings throughout the day. For more information about the BTIG Digital Health Forum, or to register to attend, please visit the BTIG website. For mor
Funded collaboration will leverage current FDA partnership to include additional LAI technologies Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has been awarded a newly funded grant from the U.S. Food and Drug Administration (FDA) to use physiologically based pharmacokinetic (PBPK) approaches in GastroPlus® to build and validate mechanistic in vitro-in vivo correlations (IVIVCs) for long-acting injectable (LAI) technologies through a joint proposal with the University of Connecticut's School of Pharmacy, D
Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O'Connor, chief executive officer, will participate in a fireside chat at the Stephens Annual Investment Conference in Nashville, TN, on Wednesday, November 20, 2024, at 12:00 p.m. Eastern Time. In addition, Mr. O'Connor will host one-on-one meetings with investors throughout the day. The live audio webcast of Mr. O'Connor's fireside chat can be accessed via this link and also on the Investors page of the Simulations Plus website where the replay will be avai
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
Fiscal 2024 revenue grew 18% year-over-year to $70 million, with diluted earnings per share (EPS) of $0.49 Provides fiscal 2025 revenue guidance of $90 to $93 million (+28% to +33%) and adjusted diluted EPS guidance of $1.07 to $1.20 Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its fourth quarter and fiscal 2024, ended August 31, 2024. Fourth Quarter 2024 Financial Highlights (compared to fourth quarter 2023) Total revenue increased 19% to $18.7 million Software revenue increased 6% to $
Conference call to be on Wednesday, October 23, 2024, at 5 p.m. EDT Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), announced today that it will report fourth quarter and fiscal 2024 financial results after the market close on Wednesday, October 23, 2024. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) or by clicking on this Call me™ link to request a return call. The webcast can be access
Total revenue of $18.5 million and diluted earnings per share (EPS) of $0.15 Maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today reported financial results for its third quarter fiscal 2024, ended May 31, 2024. Third Quarter 2024 Financial Highlights (compared to third quarter 2023) Total revenue increased 14% to $18.5 million Software revenue increased 12% to $11.9 million, representing 64% of total revenue Services revenue increase
10-K - Simulations Plus, Inc. (0001023459) (Filer)
8-K - Simulations Plus, Inc. (0001023459) (Filer)
8-K - Simulations Plus, Inc. (0001023459) (Filer)
QHP Capital, L.P. ("QHP"), an investor in technology and services companies in the life sciences and healthcare sectors, today announced its sale of Pro-ficiency, LLC ("Pro-ficiency" or the "Company"), a leader in providing tech-enabled training and compliance solutions for clinical trial investigators and site staff, to Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy. Michael Raymer, Chief Executive Officer of Pro-ficiency, said, "We are excited to join the Simulations Plus team, which has a well-established and recognized leadership position in modeling and simulations wi
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), announced today the appointment of Will Frederick as chief financial officer (CFO), succeeding John Kneisel, who retires after seven years with the company. Will Frederick brings more than 25 years of financial leadership experience to the company. He has a proven track record of developing and implementing strategies to drive revenue growth, increase profitability, managing merger & acquisition activities and achieving corporate objectives. He has global experience with both publicly traded and privately held companies including Pharsight, Entelos, Avaya, The Walt Disney Company and Ford Motor Company, among